Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Generic Name:	**clostridium botulinum neurotoxin type A**
Brand Name:	**Xeomin**
Strength:	100LD50 units per vial powder for solution for injection
Manufacturer:	Merz Pharmaceuticals GmbH
Indication:	Symptomatic management of blepharospsm (New indication)
Rapid Review:	Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	20/10/2009	15/01/2010	EO decision rendered	Listed on the Ontario Drug Benefit Formulary as a Limited Use Benefit

Rapid Review:
Details of the Rapid Review process can be found at:
www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html

Review Status:
- *Screening – Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.*
- *Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.*
- *Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.*
- *Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.*
- *Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.*
- *Executive Officer (EO) decision rendered.*

Funding Decision:
The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision can be found at: www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html

Ontario

Updated: May 19, 2011